oncbrain — oncology meeting digest

PrTK03 (aglatimagene besadenovec + EBRT)

Thu, 04 Jun 2026 00:00:00 GMT

[Practice-changing] DFS HR 0.70 (0.52–0.94), p=0.016 favoring aglatimagene + valacyclovir + EBRT vs placebo in intermediate/high-risk localized prostate cancer. Eligible: Intermediate/high-risk localized prostate cancer, ECOG 0–2, planning definitive

AREST

Thu, 04 Jun 2026 00:00:00 GMT

[Practice-changing] 3-yr LRFS 89.2% vs 80.9%, HR 0.52 (p=0.02) favoring adj RT in pT1-2 pN0 OSCC with intermediate-risk features; DFS/OS NS. Eligible: pT1-2 pN0 OSCC, intermediate-risk (DOI/PNI/LVE/poor diff), post-curative surgery

RASolute 302

Sun, 31 May 2026 00:00:00 GMT

[Practice-changing] Daraxonrasib vs IC chemo in 2L RAS G12 mPDAC: mOS 13.2 vs 6.6 mo, HR 0.40 (0.30-0.54), p<0.001. Eligible: Prev-treated metastatic PDAC, RAS G12 mutation, ≥1 prior systemic line

TALAPRO-3

Sat, 30 May 2026 00:00:00 GMT

[Practice-changing] 3yr rPFS 77% vs 56% (HR 0.48, p<0.001) favoring talazoparib+enza+ADT in HRR-deficient mHSPC. Eligible: HRR-deficient metastatic hormone-sensitive prostate cancer

ROADS

Sat, 30 May 2026 00:00:00 GMT

[Practice-changing] Surg bed recurrence 1% (GT) vs 12% (SRS); 2yr OS 62% vs 36% favoring GammaTile in resected brain mets >2cm. Eligible: Resected brain mets >2cm

NRG/RTOG 1005

Mon, 18 May 2026 00:00:00 GMT

[Practice-changing] 7-yr IBR 2.6% vs 2.2%, HR 1.31 (90% CI 0.84-2.04); concurrent boost noninferior, reducing treatment to 15 fractions. Eligible: Post-lumpectomy high-risk early breast: grade 3, ER-neg, LVI, or close margins